Literature DB >> 19618089

Tumor-suppressive microRNAs in Lung cancer: diagnostic and therapeutic opportunities.

Lorenzo F Sempere1, Xi Liu, Ethan Dmitrovsky.   

Abstract

Lung cancer is the leading cause of cancer-related death for both men and women in the U.S. As for many other cancer types, lung cancer is not a single disease, but rather a variety of diseases that present different histopathological, molecular and clinical characteristics. Improved diagnostic and therapeutic tools are needed to manage and treat lung cancer patients. microRNAs are a recently discovered class of short, noncoding RNAs that constitute a novel and functionally important layer of gene regulation. Using new mouse transgenic models for lung cancer, Liu and colleagues reported a genome-wide microRNA expression analysis and identified a signature of down-regulated microRNAs in lung cancer tissues relative to adjacent normal lung. This signature was validated in clinical specimens from lung cancer patients, underscoring the relevance of this profile to human lung cancer. In vitro experiments demonstrated that restoring miR-34c, miR-145, or miR-142-5p expression markedly diminished proliferation of lung cancer cell lines. Here, we discuss the clinical implications of these findings for lung cancer biology, therapy, and prevention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19618089      PMCID: PMC3909732          DOI: 10.1100/tsw.2009.88

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


  11 in total

Review 1.  microRNAs join the p53 network--another piece in the tumour-suppression puzzle.

Authors:  Lin He; Xingyue He; Scott W Lowe; Gregory J Hannon
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

Review 2.  Origins and Mechanisms of miRNAs and siRNAs.

Authors:  Richard W Carthew; Erik J Sontheimer
Journal:  Cell       Date:  2009-02-20       Impact factor: 41.582

Review 3.  MicroRNA silencing in primates: towards development of novel therapeutics.

Authors:  Andreas Petri; Morten Lindow; Sakari Kauppinen
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

Review 4.  MicroRNAs and cancer: profile, profile, profile.

Authors:  Elisa Barbarotto; Thomas D Schmittgen; George A Calin
Journal:  Int J Cancer       Date:  2008-03-01       Impact factor: 7.396

5.  Uncovering growth-suppressive MicroRNAs in lung cancer.

Authors:  Xi Liu; Lorenzo F Sempere; Fabrizio Galimberti; Sarah J Freemantle; Candice Black; Konstantin H Dragnev; Yan Ma; Steven Fiering; Vincent Memoli; Hua Li; James DiRenzo; Murray Korc; Charles N Cole; Mads Bak; Sakari Kauppinen; Ethan Dmitrovsky
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

6.  p53 represses c-Myc through induction of the tumor suppressor miR-145.

Authors:  Mohit Sachdeva; Shoumin Zhu; Fangting Wu; Hailong Wu; Vijay Walia; Sumit Kumar; Randolph Elble; Kounosuke Watabe; Yin-Yuan Mo
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-06       Impact factor: 11.205

7.  Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas.

Authors:  Yan Ma; Steven Fiering; Candice Black; Xi Liu; Ziqiang Yuan; Vincent A Memoli; David J Robbins; Heather A Bentley; Gregory J Tsongalis; Eugene Demidenko; Sarah J Freemantle; Ethan Dmitrovsky
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-27       Impact factor: 11.205

8.  Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer.

Authors:  Lorenzo F Sempere; Mette Christensen; Asli Silahtaroglu; Mads Bak; Catherine V Heath; Gary Schwartz; Wendy Wells; Sakari Kauppinen; Charles N Cole
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

Review 9.  Locked nucleic acid: high-affinity targeting of complementary RNA for RNomics.

Authors:  S Kauppinen; B Vester; J Wengel
Journal:  Handb Exp Pharmacol       Date:  2006

10.  MicroRNAs and cancer: short RNAs go a long way.

Authors:  Andrea Ventura; Tyler Jacks
Journal:  Cell       Date:  2009-02-20       Impact factor: 41.582

View more
  6 in total

1.  miRNA signatures associate with pathogenesis and progression of osteosarcoma.

Authors:  Kevin B Jones; Zaidoun Salah; Sara Del Mare; Marco Galasso; Eugenio Gaudio; Gerard J Nuovo; Francesca Lovat; Kimberly LeBlanc; Jeff Palatini; R Lor Randall; Stefano Volinia; Gary S Stein; Carlo M Croce; Jane B Lian; Rami I Aqeilan
Journal:  Cancer Res       Date:  2012-02-20       Impact factor: 12.701

2.  MicroRNAs - Important Molecules in Lung Cancer Research.

Authors:  Petra Leidinger; Andreas Keller; Eckart Meese
Journal:  Front Genet       Date:  2012-01-23       Impact factor: 4.599

3.  A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer.

Authors:  Debmalya Barh; Neha Jain; Sandeep Tiwari; John K Field; Elena Padin-Iruegas; Alvaro Ruibal; Rafael López; Michel Herranz; Antaripa Bhattacharya; Lucky Juneja; Cedric Viero; Artur Silva; Anderson Miyoshi; Anil Kumar; Kenneth Blum; Vasco Azevedo; Preetam Ghosh; Triantafillos Liloglou
Journal:  BMC Genomics       Date:  2013-10-25       Impact factor: 3.969

4.  Changes in miRNA in the lung and whole blood after whole thorax irradiation in rats.

Authors:  Feng Gao; Pengyuan Liu; Jayashree Narayanan; Meiying Yang; Brian L Fish; Yong Liu; Mingyu Liang; Elizabeth R Jacobs; Meetha Medhora
Journal:  Sci Rep       Date:  2017-03-17       Impact factor: 4.379

5.  Stromal Expression of miR-143/145 Promotes Neoangiogenesis in Lung Cancer Development.

Authors:  Nadya Dimitrova; Vasilena Gocheva; Arjun Bhutkar; Rebecca Resnick; Robyn M Jong; Kathryn M Miller; Jordan Bendor; Tyler Jacks
Journal:  Cancer Discov       Date:  2015-11-19       Impact factor: 39.397

6.  miR-34c attenuates epithelial-mesenchymal transition and kidney fibrosis with ureteral obstruction.

Authors:  Ryuji Morizane; Shizuka Fujii; Toshiaki Monkawa; Ken Hiratsuka; Shintaro Yamaguchi; Koichiro Homma; Hiroshi Itoh
Journal:  Sci Rep       Date:  2014-04-03       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.